Suppression of breast tumor growth and metastasis by an engineered transcription factor

PLoS ONE

Volumn 6, Issue 9, 2011, Pages

  Beltran, Adriana S ^a   Russo, Angela ^c   Lara, Haydee ^a,d   Fan, Cheng ^b   Lizardi, Paul M ^e   Blancafort, Pilar ^a,b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^d CENTRO DE INVESTIGACIÓN CIENTÍFICA Y DE EDUCACIÓN SUPERIOR DE ENSENADA   (Mexico)

^e YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTIFICIAL TRANSCRIPTION FACTOR 126; COMPLEMENTARY DNA; DOXYCYCLINE; ESTROGEN RECEPTOR; MASPIN; MICRORNA; RETROVIRUS VECTOR; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; SERINE PROTEINASE INHIBITOR; SERPIN B5; SERPIN-B5;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CARNS1 GENE; CONTROLLED STUDY; DACT3 GENE; DOWN REGULATION; EPIGENETICS; FEMALE; GENE EXPRESSION; GENE SILENCING; GENETIC ENGINEERING; GENETIC TRANSDUCTION; IMMUNE DEFICIENCY; METASTASIS INHIBITION; MOUSE; NERVE CELL; NONHUMAN; PREDICTION; PROGNOSIS; PROMOTER REGION; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SLC8A2 GENE; TRIPLE NEGATIVE BREAST CANCER; TUMOR SUPPRESSOR GENE; UPREGULATION; ANIMAL; BREAST TUMOR; CANCER TRANSPLANTATION; CHEMISTRY; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETIC TRANSCRIPTION; HUMAN; HUMAN GENOME; METABOLISM; METASTASIS; MOUSE MUTANT; MULTIGENE FAMILY; PROTEIN ENGINEERING; TUMOR CELL LINE;

MUS; PYRONIA TITHONUS;

ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; EPIGENESIS, GENETIC; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE SILENCING; GENOME, HUMAN; HUMANS; MICE; MICE, SCID; MULTIGENE FAMILY; NEOPLASM METASTASIS; NEOPLASM TRANSPLANTATION; PROTEIN ENGINEERING; RECEPTORS, ESTROGEN; SERPINS; TRANSCRIPTION FACTORS; TRANSCRIPTION, GENETIC;

EID: 80052768726     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0024595     Document Type: Article

References (50)

1. Sager R, Sheng S, Pemberton P, Hendrix MJ, (1997) Maspin. A tumor suppressing serpin. Adv Exp Med Biol 425: 77-88.
2. Cher ML, Biliran HR Jr, Bhagat S, Meng Y, Che M, et al. (2003) Maspin expression inhibits osteolysis, tumor growth, and angiogenesis in a model of prostate cancer bone metastasis. Proc Natl Acad Sci U S A 100: 7847-7852.
3. Zhang M, Volpert O, Shi YH, Bouck N, (2000) Maspin is an angiogenesis inhibitor. Nat Med 6: 196-199.
4. Nakagawa M, Katakura H, Adachi M, Takenaka K, Yanagihara K, et al. (2006) Maspin expression and its clinical significance in non-small cell lung cancer. Ann Surg Oncol 13: 1517-1523.
5. Machtens S, Serth J, Bokemeyer C, Bathke W, Minssen A, et al. (2001) Expression of the p53 and Maspin protein in primary prostate cancer: correlation with clinical features. Int J Cancer 95: 337-342.
6. Sharma G, Mirza S, Parshad R, Srivastava A, Gupta SD, et al. (2011) Clinical significance of Maspin promoter methylation and loss of its protein expression in invasive ductal breast carcinoma: correlation with VEGF-A and MTA1 expression. Tumour Biol 32: 23-32.
7. Zhang M, Maass N, Magit D, Sager R, (1997) Transactivation through Ets and Ap1 transcription sites determines the expression of the tumor-suppressing gene maspin. Cell Growth Differ 8: 179-186.
8. Domann FE, Rice JC, Hendrix MJ, Futscher BW, (2000) Epigenetic silencing of maspin gene expression in human breast cancers. Int J Cancer 85: 805-810.
9. Futscher BW, Oshiro MM, Wozniak RJ, Holtan N, Hanigan CL, et al. (2002) Role for DNA methylation in the control of cell type specific maspin expression. Nat Genet 31: 175-179.
10. Wozniak RJ, Klimecki WT, Lau SS, Feinstein Y, Futscher BW, (2007) 5-Aza-2′-deoxycytidine-mediated reductions in G9A histone methyltransferase and histone H3 K9 di-methylation levels are linked to tumor suppressor gene reactivation. Oncogene 26: 77-90.
11. Beltran A, Liu Y, Parikh S, Temple B, Blancafort P, (2006) Interrogating genomes with combinatorial artificial transcription factor libraries: asking zinc finger questions. Assay Drug Dev Technol 4: 317-331.
12. Beltran A, Parikh S, Liu Y, Cuevas BD, Johnson GL, et al. (2007) Re-activation of a dormant tumor suppressor gene maspin by designed transcription factors. Oncogene 26: 2791-2798.
13. Beltran AS, (2011) Reactivation of MASPIN in non-small cell lung carcinoma (NSCLC) cells by artificial transcription factors (ATFs). Epigenetics 6.
14. Beltran AS, Sun X, Lizardi PM, Blancafort P, (2008) Reprogramming epigenetic silencing: artificial transcription factors synergize with chromatin remodeling drugs to reactivate the tumor suppressor mammary serine protease inhibitor. Mol Cancer Ther 7: 1080-1090.
15. Beltran AS, Blancafort P, (2010) Remodeling genomes with artificial transcription factors (ATFs). Methods Mol Biol 649: 163-182.
16. Nam E, Park C, (2010) Maspin Suppresses Survival of Lung Cancer Cells through Modulation of Akt Pathway. Cancer Res Treat 42: 42-47.
17. Romani AA, Soliani P, Desenzani S, Borghetti AF, Crafa P, (2006) The associated expression of Maspin and Bax proteins as a potential prognostic factor in intrahepatic cholangiocarcinoma. BMC Cancer 6: 255.
18. Bailey CM, Khalkhali-Ellis Z, Seftor EA, Hendrix MJ, (2006) Biological functions of maspin. J Cell Physiol 209: 617-624.
19. Seftor RE, Seftor EA, Sheng S, Pemberton PA, Sager R, et al. (1998) maspin suppresses the invasive phenotype of human breast carcinoma. Cancer Res 58: 5681-5685.
20. Prat A, Parker JS, Karginova O, Fan C, Livasy C, et al. (2010) Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancer. Breast Cancer Res 12: R68.
21. Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, et al. (2006) A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell 10: 515-527.
22. Hennessy BT, Gonzalez-Angulo AM, Stemke-Hale K, Gilcrease MZ, Krishnamurthy S, et al. (2009) Characterization of a naturally occurring breast cancer subset enriched in epithelial-to-mesenchymal transition and stem cell characteristics. Cancer Res 69: 4116-4124.
23. Leone V, D'Angelo D, Rubio I, de Freitas PM, Federico A, et al. (2011) MiR-1 Is a Tumor Suppressor in Thyroid Carcinogenesis Targeting CCND2, CXCR4, and SDF-1{alpha}. J Clin Endocrinol Metab.
24. Nohata N, Sone Y, Hanazawa T, Fuse M, Kikkawa N, et al. (2011) miR-1 as a tumor suppressive microRNA targeting TAGLN2 in head and neck squamous cell carcinoma. Oncotarget 2: 29-42.
25. Liu C, Kelnar K, Liu B, Chen X, Calhoun-Davis T, et al. (2011) The microRNA miR-34a inhibits prostate cancer stem cells and metastasis by directly repressing CD44. Nat Med 17: 211-215.
26. Ma L, Teruya-Feldstein J, Weinberg RA, (2007) Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature 449: 682-688.
27. Ambasudhan R, Talantova M, Coleman R, Yuan X, Zhu S, et al. (2011) Direct Reprogramming of Adult Human Fibroblasts to Functional Neurons under Defined Conditions. Cell Stem Cell 9: 113-118.
28. Goulet B, Kennette W, Ablack A, Postenka CO, Hague MN, et al. (2011) Nuclear localization of maspin is essential for its inhibition of tumor growth and metastasis. Lab Invest 91: 1181-1187.
29. Qu M, Jiao H, Zhao J, Ren ZP, Smits A, et al. (2010) Molecular genetic and epigenetic analysis of NCX2/SLC8A2 at 19q13.3 in human gliomas. Neuropathol Appl Neurobiol 36: 198-210.
30. Guiotto A, Calderan A, Ruzza P, Borin G, (2005) Carnosine and carnosine-related antioxidants: a review. Curr Med Chem 12: 2293-2315.
31. Hipkiss AR, (2007) Could carnosine or related structures suppress Alzheimer's disease? J Alzheimers Dis 11: 229-240.
32. Renner C, Asperger A, Seyffarth A, Meixensberger J, Gebhardt R, et al. (2010) Carnosine inhibits ATP production in cells from malignant glioma. Neurol Res 32: 101-105.
33. Renner C, Zemitzsch N, Fuchs B, Geiger KD, Hermes M, et al. (2010) Carnosine retards tumor growth in vivo in an NIH3T3-HER2/neu mouse model. Mol Cancer 9: 2.
34. Schaefer JS, Zhang M, (2006) Targeting maspin in endothelial cells to induce cell apoptosis. Expert Opin Ther Targets 10: 401-408.
35. Jiang X, Tan J, Li J, Kivimae S, Yang X, et al. (2008) DACT3 is an epigenetic regulator of Wnt/beta-catenin signaling in colorectal cancer and is a therapeutic target of histone modifications. Cancer Cell 13: 529-541.
36. Takebe N, Warren RQ, Ivy SP, (2011) Breast cancer growth and metastasis: interplay between cancer stem cells, embryonic signaling pathways and epithelial-to-mesenchymal transition. Breast Cancer Res 13: 211.
37. Kalyanaraman S, Copeland NG, Gilbert DG, Jenkins NA, Gautam N, (1998) Structure and chromosomal localization of mouse G protein subunit gamma 4 gene. Genomics 49: 147-151.
38. McKenzie S, Sakamoto S, Kyprianou N, (2008) Maspin modulates prostate cancer cell apoptotic and angiogenic response to hypoxia via targeting AKT. Oncogene 27: 7171-7179.
39. Maina EN, Morris MR, Zatyka M, Raval RR, Banks RE, et al. (2005) Identification of novel VHL target genes and relationship to hypoxic response pathways. Oncogene 24: 4549-4558.
40. Tomomura M, Morita N, Yoshikawa F, Konishi A, Akiyama H, et al. (2007) Structural and functional analysis of the apoptosis-associated tyrosine kinase (AATYK) family. Neuroscience 148: 510-521.
41. Damiano L, Di Stefano P, Camacho Leal MP, Barba M, Mainiero F, et al. (2010) p140Cap dual regulation of E-cadherin/EGFR cross-talk and Ras signalling in tumour cell scatter and proliferation. Oncogene 29: 3677-3690.
42. Jaworski J, Kapitein LC, Gouveia SM, Dortland BR, Wulf PS, et al. (2009) Dynamic microtubules regulate dendritic spine morphology and synaptic plasticity. Neuron 61: 85-100.
43. Bastian I, Tam Tam S, Zhou XF, Kazenwadel J, Van der Hoek M, et al. (2011) Differential expression ofv microRNA-1 in dorsal root ganglion neurons. Histochem Cell Biol 135: 37-45.
44. Ghosh T, Soni K, Scaria V, Halimani M, Bhattacharjee C, et al. (2008) MicroRNA-mediated up-regulation of an alternatively polyadenylated variant of the mouse cytoplasmic {beta}-actin gene. Nucleic Acids Res 36: 6318-6332.
45. Li X, Yin S, Meng Y, Sakr W, Sheng S, (2006) Endogenous inhibition of histone deacetylase 1 by tumor-suppressive maspin. Cancer Res 66: 9323-9329.
46. Hu Z, Fan C, Oh DS, Marron JS, He X, et al. (2006) The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 7: 96.
47. Fan C, Prat A, Parker JS, Liu Y, Carey LA, et al. (2011) Building prognostic models for breast cancer patients using clinical variables and hundreds of gene expression signatures. BMC Med Genomics 4: 3.
48. van 't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, et al. (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415: 530-536.
49. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, et al. (2002) A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 347: 1999-2009.
50. Eisen MB, Spellman PT, Brown PO, Botstein D, (1998) Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci U S A 95: 14863-14868.